Mirae Asset Group

Mirae Asset (未来资产) is a global investment group that appears in elsewhere's corpus primarily as a growth-stage co-investor in Chinese tech and biotech deals from 2020 to 2022. It participated in XtalPi's $318.8 million Series C in September 2020, a round that 五源资本 described as setting a global funding record for AI drug discovery . The firm also followed on in CloudWalk Group's roughly $600 million Series C2 in April 2021 , Abogen Biosciences' $300 million Series C+ in late 2021 , and Hanbo Semiconductor's 1.6 billion RMB Series B rounds in early 2022 . In each case it invested alongside major Chinese funds such as 五源资本, 软银愿景基金, and 红杉中国. The retrieved material does not specify its headquarters, AUM, or whether it operates as an asset manager, corporate entity, or dedicated venture arm.